These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28063135)

  • 41. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
    Pei Y; Agner BR; Luo B; Dong X; Li D; Liu J; Liu L; Liu M; Lu Y; Nishida T; Xu X; Mu Y
    Diabetes Obes Metab; 2021 Dec; 23(12):2687-2696. PubMed ID: 34387411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
    Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
    Haldrup S; Lapolla A; Gundgaard J; Wolden ML
    J Med Econ; 2020 Mar; 23(3):271-279. PubMed ID: 31526202
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL; Sauriol L; Minshall ME
    Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E; Weatherley-Jones E; Chilcott J; Beverley C
    Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
    Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
    Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
    Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
    Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.
    Wang R; Luo S; Xiao Z; Zhou Z
    Diabetes Metab Res Rev; 2024 Mar; 40(3):e3752. PubMed ID: 38013215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
    King AB; Philis-Tsimikas A; Kilpatrick ES; Langbakke IH; Begtrup K; Vilsbøll T
    Diabetes Technol Ther; 2017 Apr; 19(4):255-264. PubMed ID: 28282219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes.
    Cheng H; Wan X; Ma J; Wu B
    Clin Ther; 2019 Mar; 41(3):445-455.e4. PubMed ID: 30713016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
    J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
    Candido R; Nicolucci A; Larosa M; Rossi MC; Napoli R;
    Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1846-1853. PubMed ID: 38693036
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
    Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
    Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
    Harris S; Abrahamson MJ; Ceriello A; Charpentier G; Evans M; Lehmann R; Liebl A; Linjawi S; Holt RIG; Hosszúfalusi N; Rutten G; Vilsbøll T
    Drugs; 2020 Feb; 80(2):147-165. PubMed ID: 31960258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.